Con­struc­tion on Mer­ck­'s Lon­don re­search hub set to be­gin in April 2023

3 years ago
R&D
Discovery

#JPM23: Did the IRA kill that drug?

3 years ago

Pi­o­neer­ing biotech icon George Scan­gos hands in his re­tire­ment pa­pers — and this time it’s for re­al

3 years ago
People
Bioregnum

For­mer Deep­Mind in­tern launch­es Atom­ic AI to 'parse' RNA struc­ture for new small mol­e­cules

3 years ago
Financing
Startups

KSQ Ther­a­peu­tics sells ear­ly-stage tar­get­ed ther­a­pies to Japan's Ono

3 years ago
Deals

‘Silo­ing is just so out­dat­ed’: New $350M VC fund aims to dig­i­tize life sci­ences

3 years ago
Financing
Startups

A stem cell pi­o­neer sent an ex­per­i­ment in­to space. Pa­tients are the next fron­tier

3 years ago
People
Cell/Gene Tx

J&J re­it­er­ates 2025 sales goal de­spite loom­ing Ste­lara ex­clu­siv­i­ty loss, glob­al eco­nom­ic chal­lenges

3 years ago
Pharma

FDA emails show how vac­cine leader ques­tioned 'hy­per-ac­cel­er­at­ed' 2021 re­view of Pfiz­er shot

3 years ago
Coronavirus

Pfiz­er taps Pink, Michael Phelps and oth­er celebri­ties in lat­est Covid cam­paign

3 years ago
Pharma
Marketing

Can­cer cell-based ther­a­pies com­ing in­to 'im­por­tan­t' year for R&D, say SVB an­a­lysts

3 years ago
Pharma
Cell/Gene Tx

Eli Lil­ly in­vests $450M to ex­pand its North Car­oli­na Re­search Tri­an­gle man­u­fac­tur­ing site

3 years ago
Financing
Manufacturing

San­doz signs deal for an­ti­fun­gal from Astel­las in buff-up of an­ti-in­fec­tives port­fo­lio

3 years ago
Deals
Pharma

No­var­tis pe­ti­tions Supreme Court in ef­fort to 'vig­or­ous­ly de­fend' Gilenya patent

3 years ago
Pharma
FDA+

Q&A: As­traZeneca res­pi­ra­to­ry/im­munol­o­gy mar­ket­ing chief talks ad strate­gies with in­flu­encers, per­son­al­iza­tion and ...

3 years ago
Pharma
Marketing

Mar­ket­ingRx: Bio­gen's new CEO talks DTC for de­pres­sion drug can­di­date; Ab­b­Vie de­buts Skyrizi TV ad for Crohn’s

3 years ago
Pharma
Marketing

Ax­cel­la seeks 'light speed' swing at long Covid, but needs cash

3 years ago
R&D
Coronavirus

CymaBay looks to raise $85M as liv­er drug's PhI­II read­out looms

3 years ago
Financing
R&D

Crushed by PhI­II an­tibi­ot­ic flop, PolyPid says it got FDA sup­port for a come­back — by fo­cus­ing on sub­group

3 years ago
R&D

Finch throws in the tow­el on mi­cro­bio­me jour­ney, lets go of 77 em­ploy­ees

3 years ago
People
R&D

#JPM23: Fire­side chat with Ei­sai's Ivan Che­ung

3 years ago
R&D

Failed deal, bid­ding war paved the way for Ipsen's $952M rare dis­ease buy­out

3 years ago
Deals

Fol­low­ing pos­i­tive da­ta for pul­monary fi­bro­sis drug, Pli­ant to sell $175M in stock

3 years ago
Financing

How the price of As­traZeneca's buy­out of Cin­Cor fell by $1.4B

3 years ago
Deals
First page Previous page 386387388389390391392 Next page Last page
A service from the Financial Times